Reading ALT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALT free→Reading ALT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALT free→QuarterlyIQ Insights · ALT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition On May 13, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
Entry into a Material Definitive Agreement. On April 22, 2026, Altimmune, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell (i) 64,250,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and accompanying common stock wa…
Results of Operations and Financial Condition On March 5, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fourth quarter and full year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
Entry into a Material Definitive Agreement. On January 27, 2026, Altimmune, Inc. (the “Company”) entered into a Securities Purchase Agreement with a new fundamental institutional investor (the “Securities Purchase Agreement”) relating to the issuance of 12,397,920 shares of the Company’s common stock, par value of $0.0001 per share (the “Common Stock”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 4,647,534 shares of Common Stock (such shares of Common Stock issuable u…
Other Events. On December 19, 2025, the Company announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (“MASH”) at 48 weeks. Topline 48-week data from the IMPACT trial showed that treatment with pemvidutide achieved statistically significant improvements across treatment arms in key non-invasive tests (“NITs”), including Enhanced Liver Fibrosis (“EL…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 1, 2025, Altimmune, Inc. (the “Company”) announced that, effective January 1, 2026 (the “Transition Date”), Vipin K. Garg, Ph.D. will transition from his role as President and Chief Executive Officer. Dr. Garg will remain with the Company as an advisor until June 30, 2026 (the "Separation Date", and the period of time between the Transi…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information contained in Item 1.01, above, is hereby incorporated by reference.
Entry into a Material Definitive Agreement. On November 6, 2025, Altimmune, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “November 2025 Agreement”) with Leerink Partners LLC, serving as sales agent (the “Sales Agent”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of…
Termination of a Material Definitive Agreement. As previously disclosed, on February 27, 2025, the Company entered into that certain Equity Distribution Agreement (the “February 2025 Agreement”) with Leerink Partners LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated, serving as sales agents (the “February 2025 Sales Agents”) with respect to an at-the-market offerings program under which the Company may offer and sell, from time to time at its sole discretion, shares of its…
Results of Operations and Financial Condition On November 6, 2025, the Company issued a press release announcing the Company’s financial results for its third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
Entry into a Material Definitive Agreement On November 5, 2025, (the “Amendment Closing”), Altimmune, Inc. (the “Company”) entered into an amendment to the Loan and Security Agreement with Hercules Capital, Inc. (“Hercules”) and the lenders party thereto, pursuant to which the lenders will make available up to four tranches of term loans (the “Term Loan”), subject to certain terms and conditions (the “Amendment”). The Amendment modified that certain Loan and Security Agreement, dated as of Ma…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed on February 24, 2025, Altimmune, Inc.’s (the “Company’s”) former Chief Medical Officer, Dr. Scott Harris, provided the Company advance notice of his intention to retire from Altimmune as of February 28, 2026 (the “Separation Date”). On September 29, 2025, the Company announced that Christophe Arbet-Engels, MD, PhD joined the…
Results of Operations and Financial Condition On August 12, 2025, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
Other Events. On June 26, 2025, the Company released topline results from IMPACT, a Phase 2b trial in metabolic dysfunction-associated steatohepatitis (“MASH”). The Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses or placebo for 24 weeks. Treatment discontinuation rates were low, with only 9% of participants prematurely discontinui…
Entry into a Material Definitive Agreement On May 13, 2025 (“Closing Date”), the Company and certain of its subsidiaries entered into a Loan and Security Agreement (“Loan Agreement”) with Hercules Capital, Inc. (“Hercules”) and the lenders party thereto, pursuant to which the lenders will make available up to four tranches of term loans in an aggregate principal amount of $100.0 million (the “Term Loan”), subject to certain terms and conditions. Amount . The Loan Agreement provides for an agg…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information set forth in
Results of Operations and Financial Condition On May 13, 2025, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.